➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Moodys
AstraZeneca
McKinsey
Express Scripts

Last Updated: October 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,850,277


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,850,277 protect, and when does it expire?

Patent 9,850,277 protects TIBSOVO and is included in one NDA.

This patent has sixty-six patent family members in thirty-four countries.

Summary for Patent: 9,850,277
Title:Therapeutically active compositions and their methods of use
Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
Inventor(s): Popovici-Muller; Janeta (Windham, NH), Lemieux; Rene M. (Charlestown, MA), Travins; Jeremy (Southborough, MA), Cai; Zhenwei (Skillman, NJ), Cui; Dawei (Shanghai, CN), Zhou; Ding (Shanghai, CN)
Assignee: AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)
Application Number:15/279,146
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Recent additions to Drugs Protected by US Patent 9,850,277

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Servier TIBSOVO ivosidenib TABLET 211192 Jul 20, 2018 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-2350 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
Servier TIBSOVO ivosidenib TABLET 211192 Jul 20, 2018 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-2533 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Servier TIBSOVO ivosidenib TABLET 211192 Jul 20, 2018 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-2534 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
Servier TIBSOVO ivosidenib TABLET 211192 Jul 20, 2018 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-3213 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 9,850,277

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ⤷  Try it Free
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML) ⤷  Try it Free
Servier TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,850,277

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 089768 ⤷  Try it Free
Australia 2013211436 ⤷  Try it Free
Australia 2017265100 ⤷  Try it Free
Australia 2019283951 ⤷  Try it Free
Canada 2861556 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Mallinckrodt
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.